Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is a marked increase in the use of selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors in the last decade. Many newborns are likely to be exposed during pregnancy and labor. OBJECTIVE: We aimed to evaluate the association between exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors during pregnancy and the risk for persistent pulmonary hypertension of the newborn. We sought to compare the risk for persistent pulmonary hypertension of the newborn between specific selective serotonin reuptake inhibitor agents. STUDY DESIGN: MEDLINE, Embase, and Cochrane were searched up to July 2017. No language restrictions were applied. Search key words included: “SSRI,” “SNRI,” “pregnancy,” “risk,” “new‐born,” and “pulmonary hypertension.” Retrospective cohort studies and case‐control studies reporting the risk for persistent pulmonary hypertension of the newborn in the offspring of women exposed to selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors during pregnancy, were extracted. Two independent researchers identified relevant data. Random effects meta‐analysis was used to pool results. Odds ratios were calculated with subsequent 95% confidence intervals. Network meta‐analysis was conducted, incorporating direct and indirect comparisons among different selective serotonin reuptake inhibitors. The primary outcome was risk for persistent pulmonary hypertension of the newborn after exposure to selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors during pregnancy. RESULTS: A total of 11 studies were identified. A total of 156,978 women and their offspring were exposed to selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors during pregnancy. Persistent pulmonary hypertension of the newborn was detected among 452 exposed offspring, representing an incidence rate of 2.9 cases per 1000 live births and a number needed to harm of 1000. The risk for persistent pulmonary hypertension of the newborn was significantly increased in the analysis of exposure to selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor in any trimester (odds ratio, 1.82; 95% confidence interval, 1.31–2.54; I2 = 72%), as well as in analysis restricted to exposure week >20 (odds ratio, 2.08; 95% confidence interval, 1.44–3.01; I2 = 76%). In network meta‐analysis, sertraline was ranked most likely to have the lowest risk for persistent pulmonary hypertension of the newborn among the different selective serotonin reuptake inhibitors (P = .83). CONCLUSION: Exposure to selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors during pregnancy is associated with an increased risk for persistent pulmonary hypertension of the newborn. According to our findings, sertraline ranked as most likely to have the lowest risk for persistent pulmonary hypertension of the newborn compared to other selective serotonin reuptake inhibitors, suggesting it may have the best safety profile for use in pregnancy in this regard. Further studies are needed to fully establish these results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396
Interpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884
Ranking treatments in frequentist network meta-analysis works without resampling methods
Rücker, G., & Schwarzer, G. (2015) · BMC Medical Research Methodology · doi:10.1186/s12874-015-0060-8 · Cited by 1,732 · cited 1×
“The P score of a treatment can be interpreted as the mean extent of certainty that the treatment is better than another treatment, and can be used to rank a treatment within a range of treatments, measured on a scale from 0 (worst) to 1 (best).(42)”
BackgroundGaynes, B. N., Gavin, N., Meltzer-Brody, S., Lohr, K. N., Swinson, T., Gartlehner, G., Brody, S., & Miller, W. C. (2005) · PsycEXTRA Dataset · doi:10.1037/e439372005-001 · Cited by 1,211
Grigoriadis, S., VonderPorten, E. H., Mamisashvili, L., Tomlinson, G., Dennis, C.-L., Koren, G., Steiner, M., Mousmanis, P., Cheung, A., Radford, K., et al. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07968 · Cited by 797
Bias in meta-analysis detected by a simple, graphical
Stuck, A. E., Rubenstein, L. Z., Wieland, D., Vandenbroucke, J. P., Irwig, L., Macaskill, P., Berry, G., Glasziou, P., Seagroatt, V., Stratton, I., et al. (1998) · BMJ · doi:10.1136/bmj.316.7129.469 · Cited by 699
Increasing use of antidepressants in pregnancy
Cooper, W. O., Willy, M. E., Pont, S. J., & Ray, W. A. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.01.033 · Cited by 458
Preskorn, S. H. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199700321-00003 · Cited by 370
Bias in case-control studies. A review.
Kopec, J. A., & Esdaile, J. M. (1990) · Journal of Epidemiology and Community Health · doi:10.1136/jech.44.3.179 · Cited by 190 · cited 1×
“The higher risk in the later studies may be attributed to the casecontrol study design, which is often susceptible to bias.(52) According to the pooled risk estimate in our analysis, PPHN is relatively rare, such that 1000 women would need to be exposed to SSRI for each additional case of PPHN.”
BackgroundReefhuis, J., Devine, O., Friedman, J. M., Louik, C., & Honein, M. A. (2015) · BMJ · doi:10.1136/bmj.h3190 · Cited by 161 · cited 1×
“Also, previous studies have suggested that among the SSRIs it is also less likely associated with congenital abnormalities.(16)”
ResultMaternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies
Hayes, R. M., Wu, P., Shelton, R. C., Cooper, W. O., Dupont, W. D., Mitchel, E., & Hartert, T. V. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.04.028 · Cited by 149
Cited by
Perinatal mental health: a review of progress and challenges
Howard, L. M., & Khalifeh, H. (2020) · World Psychiatry · doi:10.1002/wps.20769 · Cited by 1,118
ACOG Committee on Clinical Practice Guidelines–Obstetrics (2023) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000005202 · Cited by 252
Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis
Rotshild, V., Hirsh-Raccah, B., Miskin, I., Muszkat, M., & Matok, I. (2021) · Scientific Reports · doi:10.1038/s41598-021-02321-z · Cited by 233
Self-citationAssociation of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review
Dragioti, E., Solmi, M., Favaro, A., Fusar-Poli, P., Dazzan, P., Thompson, T., Stubbs, B., Firth, J., Fornaro, M., Tsartsalis, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.2859 · Cited by 215
Eleftheriou, G., Zandonella Callegher, R., Butera, R., De Santis, M., Cavaliere, A. F., Vecchio, S., Pistelli, A., Mangili, G., Bondi, E., Somaini, L., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20166565 · Cited by 17
Metadata
- Authors
- Masarwa, R., Bar-Oz, B., Gorelik, E., Reif, S., Perlman, A., & Matok, I.
- Venue
- American Journal of Obstetrics and Gynecology
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 220
- Issue
- 1
- Pages
- 57.e1-57.e13
- ISSN
- 0002-9378 (ISSN-L)
- OpenAlex
- W2889273255
- Cited by
- 92
- References
- 11
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.